Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Mangalam Drugs & Organics Ltd. ( (IN:MANGALAM) ).
Mangalam Drugs & Organics Limited has submitted to both BSE and NSE a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2025. The certificate, issued by its registrar and share transfer agent MUFG Intime India Private Limited, confirms that all securities received for dematerialisation during the quarter were duly verified, accepted or rejected, mutilated and cancelled as required, and that corresponding entries were made in the company’s register of members and listed on the appropriate stock exchanges within the prescribed timelines, underscoring the company’s adherence to securities handling and demat compliance norms.
More about Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Limited is an Indian pharmaceutical and chemicals company engaged in the manufacture of bulk drugs and intermediates, operating WHO-GMP accredited facilities with a factory located in Vapi, Gujarat. The company is listed on both BSE and the National Stock Exchange of India, giving it access to public capital markets and a broad base of shareholders.
Average Trading Volume: 44,727
Technical Sentiment Signal: Sell
Current Market Cap: 613.7M INR
For an in-depth examination of MANGALAM stock, go to TipRanks’ Overview page.